Quest PharmaTech Inc.

Equities

QPT

CA74836M1068

Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 15:59:59 2024-07-15 EDT			5-day change	1st Jan Change
0.025 ^CAD	-16.67%		0.00%	-54.55%

06-28	Quest PharmaTech Inc. Reports Earnings Results for the First Quarter Ended April 30, 2024	CI
05-30	Quest Pharmatech Inc. Announces the Appointment of Bradley J. Glass to the Board of Directors	CI

Quest Pharmatech Inc. Signs Pact for License to EGF Wound Healing Technology

January 03, 2018 at 10:27 am

Quest PharmaTech announced that it has signed an exclusive worldwide license agreement with Stanford University to develop and commercialize patented EGF wound healing technology in return for undisclosed upfront and milestone payments.

Latest news about Quest PharmaTech Inc.

Quest PharmaTech Inc. Reports Earnings Results for the First Quarter Ended April 30, 2024	06-28	CI
Quest Pharmatech Inc. Announces the Appointment of Bradley J. Glass to the Board of Directors	05-30	CI
Quest PharmaTech Inc. Reports Earnings Results for the Full Year Ended January 31, 2024	05-29	CI
Quest PharmaTech Brief: Says Quest has a 42.5% ownership interest in OncoQuest; Adds dividend income will be used by Quest for general corporate purposes	01-30	MT
Quest PharmaTech Brief: Received a cash dividend payment from OncoQuest Inc. of approximately C$685,000	01-30	MT
Quest PharmaTech Inc. Says Oregovomab Phase III Clinical Study Fails Futility Analysis	01-24	MT
Quest PharmaTech Inc. Receives Recommendations from the Data Safety Monitoring Board to Discontinue Oregovomab Phase III Clinical Study	01-23	CI
Quest PharmaTech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2023	12-13	CI
Quest PharmaTech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2023	23-09-21	CI
Quest PharmaTech Provided Product Development Update	23-07-10	MT
Quest PharmaTech Inc. Provides Product Development Update	23-07-10	CI
Quest PharmaTech Inc. Reports Earnings Results for the First Quarter Ended April 30, 2023	23-06-29	CI
Quest PharmaTech Inc. Reports Earnings Results for the Full Year Ended January 31, 2023	23-05-31	CI
Quest PharmaTech Inc. Auditor Raises 'Going Concern' Doubt	23-05-30	CI
Quest PharmaTech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2022	22-12-18	CI
Quest PharmaTech Details Bioceltran Interest Sale, Return of Photodynamic Therapy Technology License	22-09-28	MT
Sang Ho Jang acquired unknown minority stake in Bioceltran Co., Ltd from Quest PharmaTech Inc. for CAD 0.3 million.	22-09-27	CI
Quest PharmaTech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2022	22-09-26	CI
Quest PharmaTech Inc. Reports Earnings Results for the First Quarter Ended April 30, 2022	22-06-27	CI
Quest PharmaTech Inc. Reports Earnings Results for the Full Year Ended January 31, 2022	22-05-26	CI
Quest PharmaTech Inc. Auditor Raises 'Going Concern' Doubt	22-05-25	CI
Quest PharmaTech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2021	21-12-23	CI
Quest Pharmatech Inc. Reports Earnings Results for the Second Quarter Ended July 31, 2021	21-09-23	CI
Quest PharmaTech Inc. Approves Appointment of J. Mark Lievonen and Jeffrey Shon as Board of Directors	21-07-07	CI
Quest Pharmatech Inc. Reports Earnings Results for the First Quarter Ended April 30, 2021	21-06-22	CI

Chart Quest PharmaTech Inc.

Duration

Period

More charts

Company Profile

Quest PharmaTech Inc. is a Canadian biopharmaceutical company. The Company is developing products to improve the quality of life. It is developing the proprietary, MAb-AR9.6, targeting MUC16 as a diagnostic agent for cancer. MAb-AR9.6 is licensed from the University of Nebraska Medical Centre and is in late preclinical stage development. The Company has a 42.5% ownership interest in OncoQuest Inc., which is a biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest Inc.âs technology platform includes a panel of tumor antigen specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent, which is developing antibody-based immunotherapeutic products for cancer in the Greater China territory.

Sector

Biotechnology & Medical Research

Calendar

2024-09-18 - Q2 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
QUEST PHARMATECH INC.	-54.55%	3.09M
MODERNA, INC.	+26.45%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	+0.73%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+31.15%	32.4B
ICON PUBLIC LIMITED COMPANY	+22.33%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+49.32%	14.52B
MEDPACE HOLDINGS, INC.	+48.46%	13.74B
BIO-TECHNE CORPORATION	+3.67%	12.17B

Other Biotechnology & Medical Research